clinical trial · NCT06877689
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
Scholar Rock, Inc.·—·available
SMAApitegromab
brief summary
The purpose of this expanded access program (EAP) is to provide access to apitegromab for eligible patients with spinal muscular atrophy (SMA) prior to approval by the local regulatory agency . A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
started
—
primary completion
—
completion
—
last updated
Mar 14, 2025
official title
Expanded Access Protocol of Apitegromab for Patients With Spinal Muscular Atrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol